Orphan designation was granted by the European Commission to Takeda Pharma for TAK-831for the treatment of Friedreich’s ataxia

On 1 April 2019, orphan designation (EU/3/19/2148) was granted by the European Commission to Takeda Pharma A/S, Denmark, for 4-hydroxy-6-{2-[4-(trifluoromethyl)phenyl]ethyl}pyridazin-3(2H)-one (also known as TAK-831) for the treatment of Friedreich’s ataxia.

First published: 07/05/2019
EMADOC-628903358-645

Orphan designation was granted by the European Commission to Takeda Pharma for TAK-831for the treatment of Friedreich’s ataxia


Public summary of opinion on orphan designation